Innovative Therapeutics for Serious Fibrotic Diseases
Indalo Therapeutics is a biopharmaceutical company discovering and developing integrin antagonists for patients suffering from serious fibrotic diseases such as idiopathic pulmonary fibrosis (IPF) and nonalcoholic steatohepatitis (NASH). Our lead drug candidate, IDL-2965, recently demonstrated excellent safety, tolerability, and oral pharmacokinetics in healthy volunteers. Dosing has initiated in a proof-of-biology study in IPF patients. In preclinical models, IDL-2965 provides potent antifibrotic activity at low once-daily oral doses across multiple animal models of disease in vital organ systems, including lung, liver, and kidney.
Our innovative approach builds upon a solid foundation that includes:
- A history of scientific and business achievement: Our R&D leadership team was responsible for the development and approval of Esbriet® for IPF at InterMune.
- A legacy of deep target knowledge: Our founding scientists have decades of experience in the design, characterization, and development of integrin antagonists.
- Marquee investors: Atlas Venture and F-Prime have an unparalleled track record of fostering innovation.